## Jianliang Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4967202/publications.pdf

Version: 2024-02-01

840119 940134 17 482 11 16 citations h-index g-index papers 18 18 18 799 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Modulation of α7nAchR by Melatonin Alleviates Ischemia and Reperfusion-Compromised Integrity of Blood–Brain Barrier Through Inhibiting HMGB1-Mediated Microglia Activation and CRTC1-Mediated Neuronal Loss. Cellular and Molecular Neurobiology, 2022, 42, 2407-2422.	1.7	15
2	Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model. Alzheimer's Research and Therapy, 2021, 13, 114.	3.0	23
3	Panax notoginseng saponins and their applications in nervous system disorders: a narrative review. Annals of Translational Medicine, 2020, 8, 1525-1525.	0.7	20
4	Specific Knockdown of $\hat{l}_{\pm}$ -Synuclein by Peptide-Directed Proteasome Degradation Rescued Its Associated Neurotoxicity. Cell Chemical Biology, 2020, 27, 751-762.e4.	2.5	46
5	Exosomal DNA Aptamer Targeting α-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson's Disease Model. Molecular Therapy - Nucleic Acids, 2019, 17, 726-740.	2.3	77
6	Schizophrenia Patient Shows a Rare Interleukin 15 Receptor alpha Variant Disrupting Signal Transduction. Current Molecular Medicine, 2019, 19, 560-569.	0.6	3
7	Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation. Molecular Therapy - Nucleic Acids, 2018, 11, 228-242.	2.3	54
8	The Molecular Mechanism of Alpha-Synuclein Dependent Regulation of Protein Phosphatase 2A Activity. Cellular Physiology and Biochemistry, 2018, 47, 2613-2625.	1.1	11
9	Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson's Disease. Molecular Neurobiology, 2017, 54, 1404-1418.	1.9	40
10	Gamma rhythm low field magnetic stimulation alleviates neuropathologic changes and rescues memory and cognitive impairments in a mouse model of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 487-497.	1.8	36
11	Aptamer and its applications in neurodegenerative diseases. Cellular and Molecular Life Sciences, 2017, 74, 683-695.	2.4	49
12	A Novel Immunosuppressor, (5R)-5-Hydroxytriptolide, Alleviates Movement Disorder and Neuroinflammation in a 6-OHDA Hemiparkinsonian Rat Model., 2017, 8, 31.		13
13	Molecular basis of reactive oxygen species-induced inactivation of $\hat{l}\pm4\hat{l}^22$ nicotinic acetylcholine receptors. Free Radical Biology and Medicine, 2016, 97, 520-530.	1.3	2
14	Functional Impact of 14 Single Nucleotide Polymorphisms Causing Missense Mutations of Human $\hat{l}\pm7$ Nicotinic Receptor. PLoS ONE, 2015, 10, e0137588.	1.1	5
15	The coupling interface and pore domain codetermine theÂsingle-channel activity of the α7 nicotinic receptor. Neuropharmacology, 2015, 95, 448-458.	2.0	11
16	Triptolide treatment reduces Alzheimer's disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD. DMM Disease Models and Mechanisms, 2014, 7, 1385-1395.	1.2	50
17	The Structural Mechanism of the Cys-Loop Receptor Desensitization. Molecular Neurobiology, 2013, 48, 97-108.	1.9	26